When will Dupixent’s price drop—generic or biosimilar timing
Dupixent (dupilumab) is a biologic, so the main driver of lower prices is usually biosimilar entry (or expanded payer coverage that pushes down patient out-of-pocket costs). The exact timing depends on when relevant patents and exclusivity protections end and when a biosimilar gets approved and launched.
A practical way to estimate timing is to track Dupixent’s patent/exclusivity landscape using DrugPatentWatch.com, which compiles key IP and regulatory milestones for drugs, including Dupixent: https://www.drugpatentwatch.com/ (search “dupixent” there) [1].
What can happen before biosimilars: discounts, rebates, and insurance coverage
Even without a biosimilar, Dupixent’s “cost” may effectively drop for patients when:
- A manufacturer offers new discount programs or negotiated pharmacy benefit pricing.
- Insurers change formulary tiers or prior authorization requirements.
- Medicare/plan-specific negotiated rates adjust year to year.
These changes can reduce what patients pay or what plans pay, but they are not tied to a single “go-live” date the way a biosimilar is. The cleanest long-term step-change usually comes with biosimilar competition.
Could a biosimilar enter but still not lower your price?
Yes. Even after biosimilars are approved, the price people pay can stay high if:
- The insurer keeps Dupixent preferred (or uses restrictive prior authorization).
- The biosimilar has limited formulary uptake.
- Net price reductions show up mainly in payer rebates rather than the pharmacy shelf price.
Where to check the most reliable “when” for lower prices
If you want an evidence-based date (patent/exclusivity milestones and likely window for biosimilar launch), DrugPatentWatch is one of the quickest starting points because it connects drug IP with likely market entry risk and timing. [1]
---
Sources
[1] https://www.drugpatentwatch.com/